Submission milestone
OPKO's filing with the U.S. SEC states that, in February 2023, Nicoya notified EirGen of an investigational new drug submission to China's Center for Drug Evaluation, triggering a contractual milestone.
What the milestone means
An IND submission is one step in research and regulatory dialogue. It does not mean that a product has been approved or may be sold. Its status should be read against formal company and regulatory disclosures.
Further information
Follow formal company and regulatory updates for subsequent progress. Study design, intended settings, benefits and risks should be understood from materials appropriate to each stage.